Does an anti–epidermal growth factor receptor rechallenge approach for RAS wild-type metastatic colorectal cancer (MCRC) using panitumumab plus trifluridine-tipiracil lead to improved progression-free survival (PFS) compared with the standard-of-care trifluridine-tipiracil? The gene discussed is EGFR; the disease is metastatic colorectal cancer.